OA-19 Marrow Immune Features Are Most Informative of Early MRD Negative Treatment Response in Newly Diagnosed TE Patients: Insights from the UKMRA Phase 3 RADAR Study

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI:10.1016/S2152-2650(24)01860-3

Dipal Mehta, Stephen Henderson, Jasmin Rahman, Emma Lyon, Elise Rees, Kane Foster, Daria Galas-Filipowicz, Catherine Olivier, Lorna Barnard, Kara-Louise Royle, Robert Cicero, Doina Levinte, Jonathan Clemmens, Ruth De Tute, Christopher Parrish, Mark Drayson, Ceri Bygrave, Dean Smith, Jonathan Sive, Guy Pratt, Kwee Yong

引用次数: 0

查看原文本刊更多论文

OA-19 骨髓免疫特征对新诊断的 TE 患者的早期 MRD 阴性治疗反应最有参考价值：UKMRA第3期RADAR研究的启示

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.